# US 2016/0250165 A1 · Method of Modulating the Activity of a Nucleic Acid Molecule

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250165 A1
- Document ID: US20160250165A1
- Status: Published application
- Kind: A1
- Application number: 15/154,539
- Filed: 2016-05-13
- Published: 2016-09-01
- Earliest claimed: 2007-03-30
- Assignees: Duke University
- Applicants: Duke University
- Inventors: Bruce A. Sullenger; Sabah Oney; Tung Suet Ruby Lam; Kam Leong
- Web page: https://patentgrep.com/patent/US20160250165A1

## CPC

- A61K 31/164: of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/132: having two or more amino groups, e.g. spermidine, putrescine
- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- C07K 14/46: from vertebrates
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/94: involving narcotics {or drugs or pharmaceuticals, neurotransmitters or associated receptors}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/16: Aptamers
- C12N 2320/50: Methods for regulating/modulating their activity
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2500/20: cell-free systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates, in general, to agents that modulate the pharmacological activity of nucleic acid molecules and, in particular, to agents that bind therapeutic or diagnostic nucleic acid molecules in a sequence independent manner and modulate (e.g., inhibit or reverse) their activity. The invention also relates to compositions comprising such agents and to methods of using same.

## Claims

### Claim 1

A method of inhibiting the activity of a nucleic acid molecule (NAM) that binds to a target molecule and elicits a pharmacological effect, said method comprising contacting said NAM with a universal antidote (UA) under conditions such that said UA binds to said NAM and modifies the interaction between said NAM and said target, wherein said binding of said UA to said NAM is independent of the nucleotide sequence of said NAM and wherein said UA is a pharmaceutically acceptable positively charged protein, lipid, or natural synthetic polymer, or pharmaceutically acceptable salt thereof selected from the grog consisting of poly-L-lysine and polycationic polymers.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method according to claim 1 wherein said NAM is an aptamer, a siRNA, a microRNA, a ribozyme or an antagomir.

### Claim 4 (depends on 3)

The method according to claim 3 wherein said NAM is an aptamer.

### Claim 5 (depends on 1)

The method according to claim 1 wherein said target molecule is a peptide, protein, glycoprotein, polysaccharide or nucleic acid.

### Claim 6 (depends on 5)

The method according to claim 5 wherein said target molecule is an enzyme, hormone, receptor, adhesion molecule, metabolite, or cofactor.

### Claim 7 (depends on 5)

The method according to claim 5 wherein said target molecule is factor VIIa, factor IXa, factor Xa, factor XIa, thrombin or protein C.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method according to claim 1 wherein said UA reverses an immune system activating effect of said NAM.

### Claim 11 (depends on 2)

The method according to claim 2, wherein said UA reverses an anticoagulant and antithrombic effect of said NAM.

### Claim 12 (depends on 2)

The method according to claim 2 wherein said UA reverses an immunosuppressive effect of said NAM.

### Claim 13 (depends on 2)

The method according to claim 2 wherein said UA reverses an acetylcholine receptor blocking activity of said NAM.

### Claim 14 (depends on 1)

The method according to claim 1 wherein said contacting is effected in vivo.

### Claim 15 (depends on 14)

The method according to claim 14 wherein said UA is produced in vivo following administration to a patient in need thereof a construct comprising a nucleic acid sequence encoding said UA.

### Claim 16 (depends on 15)

The method according to claim 15 wherein said NAM is an aptamer to human factor IXa or human factor Xa.

### Claim 17 (depends on 14)

The method according to claim 14 wherein said contacting is effected in a mammal.

### Claim 18 (depends on 17)

The method according to claim 17 wherein said mammal is a human.

### Claim 19

A method of screening for a candidate UA capable of inhibiting the activity of a nucleic acid molecule (NAM) comprising contacting a test compound with a NAM and determining whether said test compound binds to said NAM, wherein a test compound that binds to said NAM in a manner independent of the nucleotide sequence of said NAM is a candidate UA, and wherein said test compound is a pharmaceutically acceptable positively charged protein, lipid, or natural and synthetic polymer, or pharmaceutically acceptable salt thereof selected from the group consisting of poly-L-lysine and polycationic polymers.

### Claim 20 (depends on 19)

The method according to claim 19 wherein said NAM is an plainer.

### Claim 21 (depends on 19)

The method according to claim 19 wherein said method comprises contacting a test compound with a first NAM and determining if said test compound binds to said first NAM, wherein a test compound that binds to said first NAM is then contacted with a second NAM having a sequence different from that of said first NAM and determining whether said test compound binds to said second NAM, wherein a test compound that hinds to said first NAM and said second NAM is a candidate UA.

### Claim 22 (depends on 19)

The method according to claim 19 wherein said UA binds said NAM with a binding constant greater than 1.0×106 M−1.
